What Is an Amylin Analog? Definition and What Research Reports
An amylin analog is a laboratory-modified version of amylin, a 37-amino-acid hormone released from pancreatic beta cells alongside insulin. Analogs are engineered to stay soluble and stable, because native human amylin aggregates. Published work describes pramlintide, an approved short-acting analog, and longer-acting investigational compounds such as cagrilintide and eloralintide, studied for effects on glucose handling, food intake and body weight. This page defines the term and summarises what the literature reports; it is educational only.
An amylin analog is a chemically modified copy of amylin, a small peptide hormone that pancreatic beta cells release into the bloodstream at the same time as insulin. Native human amylin is difficult to use as a medicine because it clumps together (aggregates) into insoluble fibrils, so chemists change a few of its building blocks to make a version that dissolves, stays stable in a vial, and still switches on the same receptors. The word "analog" simply means "a close relative, deliberately altered" — not a copy of the natural hormone, and not a different hormone altogether.
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or treatment decisions. Nothing here describes how any compound is used.
The Term in Biochemical Terms
Human amylin — also called islet amyloid polypeptide (IAPP) — is a 37-residue peptide co-secreted with insulin. A review of amylin biology described its journey from being regarded mainly as the pathological component of islet amyloid deposits in type 2 diabetes to being characterised as a physiological hormone with defined receptor pharmacology (PMID 30919775). That dual identity — amyloid-forming protein and signalling hormone — is the reason analogs exist at all.
Amylin does not have a single dedicated receptor gene. Instead, amylin receptors are formed when the calcitonin receptor associates with receptor activity-modifying proteins (RAMPs), producing the AMY1, AMY2 and AMY3 subtypes. Mutagenesis work on the amylin receptor 1 complex examined how specific residues contribute to peptide–receptor interaction, reporting a potential role for calcitonin serine 29 in that interaction (PMID 40722857). A separate pharmacology study compared peptides at human amylin receptors and reported that pramlintide, rat amylin and human amylin were active at these receptors, whereas Aβ1-42 was not (PMID 24169554).
Why the sequence is changed
The classic design problem is aggregation. Rat amylin does not form fibrils, and the first clinically developed analog, pramlintide, borrowed proline substitutions from the rat sequence to block fibril formation while retaining receptor activity. A profile of pramlintide described it as an amylin analog developed as an adjunct in diabetes care (PMID 30754127), and an earlier overview of amylin agonists framed the class as a distinct approach to diabetes pharmacology alongside insulin (PMID 15561917).
Why some analogs are long-acting
Native amylin has a very short circulating half-life. Medicinal-chemistry programmes therefore added lipid side chains, altered backbone residues, or used carrier chemistry. A study describing NN1213 reported the design of a potent, long-acting and selective analog of human amylin (PMID 38960379). A different strategy used PEGylated prodrugs of the antidiabetic peptides amylin and GLP-1, in which the peptide was released slowly from a polymer conjugate (PMID 29729352).
How the Term Is Used in Peptide Research
In the literature, "amylin analog" usually signals three things at once: the molecule is peptide-based, it engages amylin (calcitonin/RAMP) receptors, and its sequence differs from human amylin by design. Reviews of the class for obesity without diabetes covered present and future candidates and the rationale for targeting amylin signalling for body-weight regulation (PMID 39317404).
| Term | What it refers to |
|---|---|
| Amylin / IAPP | The endogenous 37-residue hormone co-secreted with insulin (PMID 30919775) |
| Amylin analog | A sequence-modified peptide built from the amylin scaffold |
| Amylin receptor agonist | Any molecule activating AMY receptors, including non-amylin scaffolds such as eloralintide (PMID 41109426) |
| AMY1-3 | Receptor complexes of the calcitonin receptor with RAMP1, 2 or 3 (PMID 40722857) |
| Long-acting analog | An analog engineered for extended exposure, e.g. cagrilintide, NN1213 (PMID 36883831) |
Where the term is misused
- Treating "amylin analog" and "GLP-1 analog" as interchangeable. They are separate peptide families acting at different receptors; a prodrug paper studied them side by side precisely because they are distinct molecules (PMID 29729352).
- Assuming every amylin receptor agonist is an amylin analog. Eloralintide (LY3841136) was described as a novel amylin receptor agonist taken from discovery to clinical proof of concept, a framing that emphasises receptor target rather than sequence ancestry (PMID 41109426).
- Equating amylin with amyloid-beta. Both aggregate, but receptor pharmacology separated them: Aβ1-42 was not active at human amylin receptors in the conditions tested, while amylin peptides were (PMID 24169554).
- Calling research-grade material equivalent to an approved product. Peptides labelled "research use only" are not the same regulatory category as an approved prescription medicine, regardless of sequence similarity.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
Pramlintide
Pramlintide is the reference point for the class: a profile article characterised it as an amylin analog studied as an adjunct to insulin therapy in diabetes (PMID 30754127), and earlier work on amylin agonists positioned the approach as complementary to insulin's actions rather than duplicating them (PMID 15561917). Because it was pharmacologically active and well characterised, researchers also used it as a probe: one study applied an amylin analog as a challenge test in Alzheimer's disease research (PMID 28503657).
Long-acting analogs and obesity research
Cagrilintide was reviewed as a long-acting amylin analog investigated for the treatment of obesity (PMID 36883831). A broader review of amylin analogs for obesity without diabetes surveyed the candidates in development and the questions still open for the class (PMID 39317404). On the discovery side, researchers reported NN1213 as a potent, long-acting and selective human amylin analog (PMID 38960379), while the eloralintide programme was reported from molecular discovery through to clinical proof of concept (PMID 41109426).
Amylin Analogs and Adverse Events: What Studies Report
Published safety-relevant findings for this class are specific to the compound and the population studied. In a human provocation study, the amylin analog pramlintide induced migraine-like attacks in patients, a finding the study reported as evidence for amylin receptor involvement in migraine biology (PMID 33772845). Reviews of the class for obesity discussed tolerability alongside efficacy considerations for long-acting analogs (PMID 39317404; PMID 36883831). Researchers have not established that findings for one analog transfer to another, since sequence, duration of action and receptor selectivity differ across the class (PMID 38960379).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRelated Terms Worth Knowing
- IAPP (islet amyloid polypeptide) — the alternative name for amylin, reflecting its role in islet amyloid deposits (PMID 30919775).
- RAMP — receptor activity-modifying protein; partners with the calcitonin receptor to create amylin receptor subtypes (PMID 40722857).
- Co-agonist / combination — describes molecules or regimens engaging more than one receptor system, such as amylin plus GLP-1 approaches discussed in class reviews (PMID 39317404).
- Prodrug — an inactive conjugate that releases the peptide over time, as in PEGylated amylin and GLP-1 constructs (PMID 29729352).
How to Read Claims About Amylin Analogs
- Check whether the source names a specific molecule or speaks about "amylin" generically; the literature is compound-specific.
- Check the model — receptor mutagenesis (PMID 40722857), cell pharmacology (PMID 24169554) and human studies (PMID 41109426) answer different questions.
- Check regulatory status: an approved product, an investigational candidate and a research-use-only chemical are three different categories.
- Check whether adverse findings, such as the migraine-like attacks reported after pramlintide (PMID 33772845), are being carried across compounds without evidence.
Again, this page defines a term and summarises published reports. It is not medical advice and does not describe use of any substance.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity (Cardiology in Review, 2024)
- Amylin analogs for the treatment of obesity without diabetes: present and future (Expert Review of Clinical Pharmacology, 2024)
- NN1213 - A Potent, Long-Acting, and Selective Analog of Human Amylin (Journal of Medicinal Chemistry, 2024)
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
- Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients (Annals of Neurology, 2021)
- PEGylated prodrugs of antidiabetic peptides amylin and GLP-1 (Journal of Controlled Release, 2018)
- Human Amylin: From Pathology to Physiology and Pharmacology (Current Protein & Peptide Science, 2019)
- An amylin analog used as a challenge test for Alzheimer's disease (Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2017)
- Pramlintide: profile of an amylin analog (Expert Review of Endocrinology & Metabolism, 2012)
- Amylin agonists: a novel approach in the treatment of diabetes (Diabetes, 2004)
- Amylin Receptor 1 Mutagenesis Revealed a Potential Role of Calcitonin Serine 29 in Receptor Interaction (Biomedicines, 2025)
- Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors (Endocrinology, 2014)
Frequently asked questions
What does "amylin analog" actually mean?▾
It means a peptide built from the amylin sequence but deliberately modified, usually to stop it aggregating or to extend how long it lasts. Reviews described amylin itself as a hormone co-secreted with insulin whose pathology-to-physiology story shaped analog design (PMID 30919775), and pramlintide was profiled as the first such analog developed clinically (PMID 30754127).
Is amylin the same as insulin?▾
No. Amylin is a separate 37-residue hormone released by the same beta cells at the same time as insulin, and it acts at different receptors formed from the calcitonin receptor plus RAMP proteins (PMID 30919775, PMID 40722857). Early work framed amylin agonists as a distinct pharmacological approach in diabetes rather than an insulin substitute (PMID 15561917).
Which amylin analogs appear most often in the literature?▾
Pramlintide is the long-established reference compound (PMID 30754127). Cagrilintide was reviewed as a long-acting amylin analog studied in obesity (PMID 36883831), NN1213 was reported as a potent, long-acting and selective human amylin analog (PMID 38960379), and eloralintide (LY3841136) was described as an amylin receptor agonist taken from discovery to clinical proof of concept (PMID 41109426).
Is every amylin receptor agonist an amylin analog?▾
Not necessarily. The term "analog" points to sequence ancestry, while "receptor agonist" points to the target. Eloralintide was reported as a novel amylin receptor agonist, a framing centred on receptor activation (PMID 41109426), and receptor pharmacology work showed that activity at human amylin receptors can be tested independently of sequence origin (PMID 24169554).
What have studies reported about adverse effects in this class?▾
Findings are compound-specific. One human study reported that the amylin analog pramlintide induced migraine-like attacks in patients, which researchers interpreted as evidence for amylin receptor involvement in migraine (PMID 33772845). Class reviews for obesity discussed tolerability alongside efficacy for long-acting analogs (PMID 39317404, PMID 36883831). This is educational information, not medical advice.
Why do chemists modify amylin instead of using the natural peptide?▾
Human amylin aggregates into fibrils and clears quickly, which complicates formulation and duration. A review traced amylin's identity as both an amyloid-forming protein and a hormone (PMID 30919775). Engineering responses included long-acting analogs such as NN1213 (PMID 38960379) and PEGylated prodrug conjugates designed to release amylin or GLP-1 gradually (PMID 29729352).
Have amylin analogs been used outside metabolic research?▾
Yes, as pharmacological probes. One study applied an amylin analog as a challenge test in Alzheimer's disease research (PMID 28503657), and separate receptor work reported that pramlintide, rat amylin and human amylin were active at human amylin receptors while Aβ1-42 was not (PMID 24169554). These were mechanistic investigations, not treatment recommendations.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.